Merck’s V920 Ebola Zaire Vaccine Receives CHMP Positive Opinion to Protect Against Ebola Virus Disease

 Merck’s V920 Ebola Zaire Vaccine Receives CHMP Positive Opinion to Protect Against Ebola Virus Disease

Merck’s V920 Ebola Zaire Vaccine Receives CHMP Positive Opinion to Protect Against Ebola Virus Disease

Shots:

  • The EMA’s CHMP has adopted the positive opinion recommending conditional marketing authorization for the V920 Ebola Zaire vaccine (rVSVΔG-ZEBOV-GP, live), indicated for active immunization of individuals ≥18yrs. to protect against EVD caused by Zaire Ebola virus
  • If EC affirmed CHMP opinion, it will grant centralized marketing authorization with unified labeling to the V920 Ebola Zaire Vaccine and will be authorized under the name Ervebo
  • V920 is a recombinant, replication-competent Ebola vaccine, consisting of a vesicular stomatitis virus to provoke a neutralizing immune response to the Ebola virus. The US FDA has accepted its BLA in Sept’2019 and granted it PR with a PDUFA date as Mar 14, 2020

Click here to­ read full press release/ article | Ref: Merck | Image: Barron

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post